CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Matthew K. Szot

Profile

Matthew K. Szot

Chief Financial Officer, Cadrenal Therapeutics, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Cadrenal Therapeutics, Inc. named Quang X. Pham to succeed Matthew K. Szot on an interim basis, effective May 28, 2026.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Cadrenal Therapeutics, Inc. (CVKD)
Pharmaceutical Preparations
Not statedFormer1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. May 28, 2026effective

    Cadrenal Therapeutics, Inc. named Quang X. Pham to succeed Matthew K. Szot on an interim basis, effective May 28, 2026. Profile of Quang X. Pham.

    Szot’s termination, the Company appointed Quang X.

    [1] Filing by Cadrenal Therapeutics, Inc., filed with the SEC on June 3, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Cadrenal Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 3, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Matthew K. Szot wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.